Viridian Therapeutics, Inc. · NASDAQ:VRDN
Viridian Therapeutics — Technical Presentation (May 2025)
14 slides from Viridian Therapeutics's technical presentation, May 20, 2025
Slide 1: THRIVE in Active TED 52-Week Follow-Up Update
THRIVE in Active TED 52-Week Follow-Up Update (May 20, 2025) Exhibit 99.2
Slide 2: Forward-looking statements
This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “pr
Slide 3: THRIVE: Veligrotug showed robust and consistent clinical activity in active TED patients
Achieved all primary and secondary endpoints with high level of statistical significance (p < 0.0001) Source: Viridian THRIVE week 15 topline data on file (interim topline database lock) & week 52 data on file (final database lock). AE = adverse event, IGF-1R = insulin-like growth factor-1 receptor,
Slide 4: THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED
D = day, mm = millimeter, TED = thyroid eye disease, W = week. THRIVE is a phase 3 randomized, controlled, double-masked trial of veligrotug in active TED Treatment Phase (12-week treatment period with primary endpoint at 15 weeks) Veligrotug n = 75 D1 W3 W6 W9 W12 Placebo n = 38 Key: Veligrotug 10
Slide 5: THRIVE baseline characteristics were well-balanced between active and placebo arms
7.8 Veligrotug (n = 75) Placebo (n = 38) Participant Demographics Age in years, mean (SD) 48.9 (12.4) 49.1 (12.5) Female sex, n (%) 56 (75%) 31 (82%) White race, n (%) 51 (68%) 19 (50%) Disease Characteristics Months since TED onset, mean (SD) 7.9 (3.7) 7.2 (3.8) Baseline proptosis by exophthalmomet
Slide 6: THRIVE efficacy results at week 15
Veligrotug (n=75) Placebo (n=38) p-value Proptosis Primary Endpoint: Proptosis responder rate (exophthalmometry)1 70% 5% p < 0.0001 Proptosis mean change from baseline (exophthalmometry) -2.89 mm -0.48 mm p < 0.0001 Diplopia Diplopia complete resolution2 54% 12% p < 0.0001 Diplopia responder rate3 6
Slide 7: Primary endpoint of proptosis responder rate met at 15 weeks
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. mm = millimeter, PBO = placebo. Primary endpoint of proptosis responder rate met at 15 weeks: 70% for patients
Slide 8: Majority of veligrotug patients had complete diplopia resolution and minimal CAS
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). Results at time points before week 15 are from post-hoc analyses and are for descriptive purposes only. CAS = clinical activity score. Majority of patients receiving veligrotug had complete resolution of diplopia a
Slide 9: Consistency between Hertel and MRI / CT proptosis measurements
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). CT = computed tomography, IGF-1R = insulin-like growth factor-1 receptor, mm = millimeter, MRI = magnetic resonance imaging. THRIVE demonstrated consistency between Hertel and MRI / CT and validates both as reliabl
Slide 10: Veligrotug generally well-tolerated at week 15, no treatment-related SAEs
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 6 unrelated SAEs in 4 participants: cellulitis, appendicitis, dyspnoea, hyperthyroidism, aortic dissection (planned surgery for known Type B aortic dissection), depression (diagnosed prior to 1st dose); Includes
Slide 11: Adverse events at week 15 with 5.5% placebo-adjusted hearing impairment rate
Source: Viridian THRIVE week 15 topline data on file (interim topline database lock). 1 Includes multiple terms aggregated using standard sets of MedDRA terms, 2 Reported as percentage of menstruating women. AE = adverse event, MedDRA= medical dictionary for regulatory activities. Veligrotug was gen
Slide 12: 70% of proptosis responders maintained response at Week 52
Source: Viridian THRIVE week 52 data on file (final database lock). 1 Responders at week 15 who still had at least a 2-millimeter (mm) reduction in proptosis compared to baseline at week 52, without worsening in the fellow eye (≥2 mm increase), as measured by exophthalmometry. Methodology is the sam
Slide 13: Appendix
m\ WEVIRIDIAN Appendix
Slide 14: Tepezza durability (label)
Source: TEPEZZA U.S. Prescribing Information. Cross-trial comparisons should be avoided due to the lack of head-to-head clinical trial data. 1 Responders at week 24 who still had at least a 2-millimeter (mm) reduction in proptosis compared to baseline at week 52 Tepezza Prescribing Information shows
Viridian Therapeutics, Inc.\DE — Technical Presentation (May 2025) on 6ix